Evotec (EVT) 주식 개요
Evotec SE는 전 세계 제약 및 생명공학 업계의 신약 발견 및 개발 파트너로 활동하고 있습니다. 자세히 보기
EVT Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Evotec SE 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €4.62 |
| 52주 최고가 | €8.57 |
| 52주 최저가 | €4.00 |
| 베타 | 1.3 |
| 1개월 변동 | -18.12% |
| 3개월 변동 | -23.37% |
| 1년 변동 | -35.83% |
| 3년 변동 | -76.56% |
| 5년 변동 | -87.08% |
| IPO 이후 변동 | -70.68% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).
내러티브 업데이트 • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Recent updates
내러티브 업데이트 • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).내러티브 업데이트 • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.내러티브 업데이트 • Apr 05
EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).내러티브 업데이트 • Mar 21
EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.
내러티브 업데이트 • Mar 07
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.내러티브 업데이트 • Feb 20
EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.내러티브 업데이트 • Feb 06
EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).내러티브 업데이트 • Jan 22
EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.내러티브 업데이트 • Jan 07
EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.내러티브 업데이트 • Dec 17
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.내러티브 업데이트 • Dec 03
EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.내러티브 업데이트 • Aug 21
Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
새로운 내러티브 • Apr 30
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.분석 기사 • Nov 10
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...분석 기사 • Nov 05
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...분석 기사 • Aug 17
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...분석 기사 • Aug 08
Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...분석 기사 • Aug 03
We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Apr 10
Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 3.1x Evotec SE ( ETR:EVT ) is a stock worth checking out...분석 기사 • Mar 05
These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jan 09
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price
With a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in Germany, you could be...주주 수익률
| EVT | DE Life Sciences | DE 시장 | |
|---|---|---|---|
| 7D | -10.8% | -4.7% | -0.9% |
| 1Y | -35.8% | -21.7% | -1.6% |
수익률 대 산업: EVT은 지난 1년 동안 -21.7%의 수익을 기록한 German Life Sciences 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: EVT은 지난 1년 동안 -1.6%를 기록한 German 시장보다 저조한 성과를 냈습니다.
주가 변동성
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 9.0% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.3% |
| 10% least volatile stocks in DE Market | 2.7% |
안정적인 주가: EVT의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.
시간에 따른 변동성: EVT의 주간 변동성(9%)은 지난 1년 동안 안정적이었지만 German 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1993 | 4,526 | Christian Wojczewski | www.evotec.com |
Evotec SE는 전 세계 제약 및 생명공학 업계의 신약 발견 및 개발 파트너로 활동하고 있습니다. 쉐어드 R&D와 저스트 에보텍 바이오로직스의 두 부문으로 운영되고 있습니다. 이 회사는 종양학, 자가면역, 암, 당뇨병, 심부전, 섬유증, 면역학, 통증 및 염증, 감염, 신장, 간, 희귀, 호흡기, 섬유성 및 대사 질환, 중추신경계 및 심장 대사 장애, 동물 및 여성 건강 등 다양한 치료 분야에서 의약품을 개발하고 있습니다.
Evotec SE 기초 지표 요약
| EVT 기초 통계 | |
|---|---|
| 시가총액 | €820.85m |
| 순이익 (TTM) | -€193.88m |
| 매출 (TTM) | €745.04m |
1.1x
주가매출비율(P/S)-4.2x
주가수익비율(P/E)EVT는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| EVT 손익계산서 (TTM) | |
|---|---|
| 매출 | €745.04m |
| 매출원가 | €665.62m |
| 총이익 | €79.42m |
| 기타 비용 | €273.29m |
| 순이익 | -€193.88m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 13, 2026
| 주당순이익(EPS) | -1.09 |
| 총이익률 | 10.66% |
| 순이익률 | -26.02% |
| 부채/자본 비율 | 55.4% |
EVT의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/17 19:27 |
| 종가 | 2026/05/15 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Evotec SE는 23명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |